Search Results
Your search for ,iII matches 9601 pages
Showing 251 - 300Overall Survival Benefit With Ivonescimab Plus Chemotherapy in Advanced Squamous NSCLC
New findings from the phase III HARMONi-6 trial presented at the 2026 ASCO Annual Meeting showed that the investigational bispecific antibody ivonescimab combined with chemotherapy significantly improved overall survival compared with tislelizumab plus chemotherapy in patients with advanced...
Daraxonrasib Extends Median Survival in Previously Treated Pancreatic Cancer
Median Overall survival was nearly doubled among patients with previously treated metastatic pancreatic cancer who received the multiselective RAS(ON) inhibitor daraxonrasib in the phase III RASolute 302 trial, the results of which were presented at the Plenary Session of the 2026 ASCO Annual...
PROTEUS: Perioperative Apalutamide Plus ADT May Set New Standard in High-Risk Localized Prostate Cancer
For decades, perioperative systemic therapy has failed to improve long-term outcomes after radical prostatectomy in high-risk localized prostate cancer. The phase III PROTEUS trial may be the first to break that pattern. Presented as LBA1 during the Plenary Session at the 2026 ASCO Annual Meeting,...
Peter Schmid, MD, PhD, FRCP, on ER-Positive HER2-Negative Early Breast Cancer: Giredestrant by Menopausal Status
Peter Schmid, MD, PhD, FRCP, of Queen Mary University of London, shares more data from the phase III lidERA BC clinical trial. This analysis focused on the efficacy and safety of giredestrant in patients with estrogen receptor (ER)-positive, HER2-negative early breast cancer, looking at both...
John M. Burke, MD, on Newly Diagnosed DLBCL: frontMIND Trial
John M. Burke, MD, of SCRI at Rocky Mountain Cancer Centers I The US Oncology Network, presents findings from the phase III frontMIND trial, which evaluated tafasitamab plus lenalidomide and R-CHOP in patients newly diagnosed with diffuse large B-cell lymphoma (Abstract LBA7000).
Adam Kibel, MD, on PROTEUS Trial in High-Risk Prostate Cancer: A Surgical Oncologist’s Perspective
Adam Kibel, MD, of Brigham and Women's Hospital, discusses findings from the phase III PROTEUS trial, which evaluated perioperative (neoadjuvant and adjuvant) apalutamide and androgen deprivation therapy vs placebo and ADT with radical prostatectomy in patients with high-risk localized or locally...
Brian M. Wolpin, MD, MPH, and Eileen M. O’Reilly, MD, on Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
Brian M. Wolpin, MD, MPH, of Dana-Farber Cancer Institute, and Eileen M. O’Reilly, MD, of Memorial Sloan Kettering Cancer Center, describe results from the phase III RASolute 302 trial, which evaluated the RAS(ON) muliselective inhibitor daraxonrasib in previously treated patients with metastatic...
Jonathan W. Goldman, MD, on RET Fusion–Positive NSCLC: Adjuvant Selpercatinib
Jonathan W. Goldman, MD, of the University of California, Los Angeles, presents event-free survival data from the primary analysis of the phase III LIBRETTO-432 trial, which investigated the efficacy of the kinase inhibitor selpercatinib in patients with stage IB–IIIA RET fusion–positive non–small...
Mary-Ellen Taplin, MD, FASCO, on High-Risk Localized or Locally Advanced Prostate Cancer: PROTEUS Trial
Mary-Ellen Taplin, MD, FASCO, of Dana-Farber Cancer Institute, presents the final analysis of the phase III PROTEUS study, which looked at perioperative (neoadjuvant and adjuvant) apalutamide plus androgen-deprivation therapy (ADT) vs placebo and ADT with radical prostatectomy in patients with...
Sanjay Popat, PhD, FRCP, on RET Fusion-Positive NSCLC: First-Line Pralsetinib
Sanjay Popat, PhD, FRCP, of the Royal Marsden Hospital & Institute of Cancer Research, talks about the findings of the phase III AcceleRET-Lung study, which looked at the oral tyrosine kinase inhibitor pralsetinib as first-line therapy for patients with RET fusion–positive advanced or...
Ramaswamy Govindan, MD, FASCO, on EGFR-Mutant NSCLC: Final Overall Survival Results From Alliance A081105
Ramaswamy Govindan, MD, FASCO, of Alvin J. Siteman Cancer Center at Washington University School of Medicine in St. Louis, presents the final overall survival results from the randomized phase III Alliance A081105 trial, which evaluated adjuvant erlotinib vs observation after complete resection of...
Pain and Health-Related QOL With Darolutamide in Metastatic Hormone-Sensitive Prostate Cancer
In analyses from the phase III ARANOTE trial reported in The Lancet Oncology, Morgans et al found that darolutamide was associated with prolonged times to worsening pain and worsening health-related quality of life (QOL) compared with placebo in patients with metastatic hormone-sensitive prostate...
First-Line Sunvozertinib in Advanced NSCLC With EGFR Exon 20 Insertion Mutations
The EGFR-targeting tyrosine kinase inhibitor sunvozertinib was more effective than standard platinum-based chemotherapy as a first-line treatment for patients with advanced non–small cell lung cancer (NSCLC) driven by EGFR exon 20 insertion mutations (EGFR exon20ins). Results from the phase III...
FDA Approves Durvalumab Plus BCG for High-Risk NMIBC
On May 28, 2026, the U.S. Food and Drug Administration (FDA) approved the PD-L1 inhibitor durvalumab (Imfinzi) in combination with bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC). Efficacy and Safety Efficacy...
Long-Term EORTC Trial Challenges Assumptions About Lymph Node Radiation Therapy in Breast Cancer
Final results from a landmark European Organisation for Research and Treatment of Cancer (EORTC) randomized trial with more than 20 years of follow-up have shown that irradiation of the internal mammary and medial supraclavicular (IM-MS) lymph nodes reduces breast cancer mortality but does not...
ASCO Congratulates 2026 Special Award Recipients
ASCO and Conquer Cancer, the ASCO Foundation, are proud to celebrate a distinguished group of individuals at the 2026 ASCO Annual Meeting. The Society will present its highest honors to researchers, educators, patient advocates, and global leaders for their career-defining excellence and tremendous ...
Patient-Reported Outcomes Support Niraparib Maintenance in Advanced Ovarian Cancer Regardless of Homologous Recombination Deficiency Status
Patient-reported outcomes from a subgroup analysis of the final analysis of the phase III PRIMA/ENGOT-OV26/GOG-3012 trial showed that first-line maintenance therapy with the PARP inhibitor niraparib did not adversely affect overall health-related quality of life in patients with newly diagnosed...
GLP-1 Receptor Agonists May Reduce Metastatic Progression in Certain Obesity-Related Cancers
Real-world data suggest that GLP-1 receptor agonists may reduce metastatic progression in certain obesity-related cancers, particularly lung, breast, colorectal, and liver cancers, according to findings presented at the 2026 ASCO Annual Meeting (Abstract 3143).1 GLP-1 receptor expression was also...
Yoga Intervention May Reduce Mood Disturbance, Anxiety, Fatigue, and Insomnia in Cancer Survivors
A 4-week structured yoga intervention program named Yoga for Cancer Survivors (YOCAS) improved overall mood disturbance, anxiety, and fatigue among cancer survivors, according to findings from a phase III randomized controlled trial presented at the 2026 ASCO Annual Meeting (Abstract 12004).1 The...
Losing Weight, Gaining Quality of Life in Early-Stage Breast Cancer
A telephone-based weight loss intervention improved physical function and other patient-reported outcomes among women with early-stage breast cancer and overweight or obesity, according to findings from the health outcomes (HO)-1 substudy of the phase III Breast Cancer WEight Loss (BWEL) trial...
ASCENDE-RT 15-Year Update Shows No Overall Survival Benefit, With ‘Borderline’ Signal for Fewer Deaths
Fifteen-year results from the phase III ASCENDE-RT trial in patients with intermediate- and high-risk localized prostate cancer receiving androgen-deprivation therapy (ADT) and pelvic external-beam radiotherapy (EBRT) show no significant overall survival advantage with a prostate brachytherapy...
Recurrence With Concurrent or Sequential Radiation Dose Escalation to the Surgical Cavity in High-Risk Early Breast Cancer
As reported in the Journal of Clinical Oncology by Vicini et al, the phase III NRG/RTOG 1005 trial has shown noninferior risk for ipsilateral breast recurrence (IBR) with concurrent vs sequential radiation dose escalation to the surgical cavity in conservative treatment of high-risk early breast...
Daraxonrasib for Previously Treated RAS-Mutated Pancreatic Cancer
In a phase I/II trial (RMC-6236-001) reported in The New England Journal of Medicine, Wolpin et al identified the safety profile of daraxonrasib and showed activity of the agent in patients with previously treated advanced RAS-mutated pancreatic ductal adenocarcinoma (PDAC). Daraxonrasib (RMC-6236) ...
Study Finds Methylphenidate-Type Psychostimulants May Reduce Cancer-Related Fatigue
A new meta-analysis published by Costa et al in JNCCN—Journal of the National Comprehensive Cancer Network provides updated evidence that methylphenidate-type psychostimulants—a class of medication that increases dopamine and norepinephrine availability in the brain—can provide meaningful relief...
Study Finds Stage IV Breast Cancer Increasing in Incidence and Proportion Over the Past Decade
A new study shows that cases of stage IV breast cancer are increasing both in incidence and as a proportion of all breast cancer diagnoses. According to the findings, published by Avila et al in JAMA Network Open, the incidence rate of stage IV breast cancer has increased significantly from 9.5...
Adding Capivasertib to Abiraterone in PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer: The Patient Experience
New analyses from the multicenter phase III CAPItello-281 trial of the AKT1/2/3 inhibitor capivasertib plus the CYP17 inhibitor abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer—now sometimes described as androgen pathway modulation–resistant (APMR) (or modulation-sensitive ...
FDA Approves Fam-Trastuzumab Deruxtecan-nxki Indications in HER2-Positive Early Breast Cancer
On May 15, 2026, the U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (T-DXd) (Enhertu) for two separate indications for the treatment of adult patients with HER2-positive early-stage breast cancer. The first indication is for the neoadjuvant treatment of adult...
Relacorilant Plus Nab-Paclitaxel Improves Overall Survival in Platinum-Resistant Ovarian Cancer
Final overall survival results from the phase III ROSELLA trial showed a statistically and clinically significant survival benefit with the selective glucocorticoid receptor antagonist relacorilant plus nab-paclitaxel vs nab-paclitaxel alone in patients with platinum-resistant ovarian cancer....
Combination Enzalutamide and Radium-223 Extends Overall Survival in Bone-Dominant mCRPC
In the final analysis of the phase III EORTC 1333/PEACE-3 trial, with a median follow-up of 58 months, the addition of radium-223 to the androgen receptor inhibitor enzalutamide significantly prolonged overall survival in patients with bone-dominant metastatic castration-resistant prostate cancer...
Neoadjuvant Single-Cycle Pembrolizumab for Stage I to III dMMR Colon Cancer
In a Danish phase II trial (RESET-C) reported in the Journal of Clinical Oncology, Gögenur et al found that a single cycle of neoadjuvant pembrolizumab was associated with pathologic complete response (pCR) in almost half of patients with stage I to III mismatch repair–deficient (dMMR) colon...
I’m Young and Have Advanced Neuroendocrine Carcinoma of the Rectum
Eight years ago, I was 33 years old, and my main health concern was a diagnosis of ankylosing spondylitis, a form of arthritis that causes stiff, painful joints in the spine. Having a chronic disease made me pay close attention to any changes in my health, so when I noticed blood in my stool, I...
National Academy of Medicine Recognizes 100 Newly Elected Members
Overview of Member Election Election to the National Academy of Medicine recognizes individuals who have demonstrated outstanding professional achievement and commitment to service. New members are elected by current members through a process that acknowledges individuals who have made major...
Can Physical Activity Reduce Cancer-Related Fatigue?
Greater physical activity—particularly walking—may reduce fatigue and improve quality of life in patients with colorectal cancer, with stronger associations observed in nonmetastatic disease. These findings were demonstrated in a longitudinal analysis of the ColoCare Study population presented by...
LLM Tool Significantly Reduces Participant Screening Burdens, Improves Enrollment for Phase III Trial in Polycythemia Vera
Synapsis AI, a medically trained, large language model (LLM)–based end-to-end system, reduced the time and effort needed to screen for eligible patients to participate in a randomized, interventional phase III clinical trial in patients with polycythemia vera (PV). Use of Synapsis AI also led to...
De-escalation, Recovery, and Robotic Surgery in Breast Cancer Care
At the American Society of Breast Surgeons (ASBrS) 27th Annual Meeting, investigators presented new findings on breast cancer surgery, postoperative recovery, and radiation treatment planning. Among the many sessions, several studies were presented during a media briefing earlier this month and are ...
Tiragolumab/Atezolizumab and Chemotherapy Fails in Advanced Nonsquamous NSCLC
As reported in JAMA Oncology by Socinski et al, the phase III SKYSCRAPER-06 trial showed no progression-free or overall survival benefit with tiragolumab, a monoclonal antibody targeting T-cell immunoreceptor with Ig and ITIM domains (immunoreceptor tyrosine-based inhibitory motifs) (TIGIT), plus...
‘Promising’ Signal Only: ctDNA in Early Breast Cancer Not Yet Ready for Clinical Use
Despite compelling prognostic associations across multiple retrospective data sets, no interventional trial has demonstrated that acting on circulating tumor DNA testing results in early breast cancer improves patient outcomes. Clinicians should therefore proceed with caution until such evidence...
Adjuvant Hepatic Arterial Infusion After Surgery for Colorectal Liver Metastases
In a French phase II trial (PACHA-01) reported in the Journal of Clinical Oncology, Gelli et al found that adjuvant hepatic infusion of oxaliplatin improved hepatic recurrence–free survival vs intravenous (IV) oxaliplatin, both combined with fluorouracil/leucovorin (LV5FU2), after curative-intent...
FDA Permits Expanded Access for Investigational Pancreatic Cancer Drug
On May 1, the U.S. Food and Drug Administration announced that it issued a “safe to proceed” letter to Revolution Medicines, allowing the sponsor to initiate an expanded access treatment protocol (EAP) for its experimental pancreatic cancer drug, daraxonrasib. In mid-April, Revolution Medicines...
On-Treatment PSA and Overall Survival in Prostate Cancer
In a post hoc analysis reported in The Lancet Oncology, Kayani et al found that on-treatment prostate-specific antigen (PSA) level was associated with overall survival in patients with metastatic or very high-risk nonmetastatic prostate adenocarcinoma from five phase III trials in the STAMPEDE...
FDA Approves Vepdegestrant for ER-Positive, HER2-Negative, ESR1-Mutated Advanced Breast Cancer
On May 1, the U.S. Food and Drug Administration (FDA) approved vepdegestrant (Veppanu), a heterobifunctional protein degrader, for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized ...
Melanoma: Gut Microbiome May Help Predict Recurrence After Immunotherapy
Gut bacterial markers may be able to predict recurrence in patients with high-risk melanoma receiving adjuvant immune checkpoint inhibition, according to study findings published in Cell. “Our study identified for the first time gut bacterial types that can serve as markers of increased recurrence ...
Lenalidomide Plus Rituximab in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-up From AUGMENT
As reported in the Journal of Clinical Oncology by Leonard et al, the 5-year follow-up of the phase III AUGMENT trial has shown continued benefit of lenalidomide plus rituximab (R2) vs rituximab with placebo (R-placebo) in patients with relapsed or refractory indolent non-Hodgkin lymphoma. Study...
Belzutifan/Lenvatinib Outperforms Cabozantinib After Checkpoint Inhibitors in Advanced Renal Cell Carcinoma
At the first and second interim analyses of the phase III LITESPARK-011 trial, treatment with the novel first-in-class hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor belzutifan plus lenvatinib improved progression-free survival, produced a higher objective response rate, and showed a trend...
MIBC: Pembrolizumab With Trimodal Therapy for Bladder Preservation
Pembrolizumab in combination with gemcitabine and concurrent hypofractionated radiation therapy and maximal transurethral resection may be safe and feasible in patients with muscle-invasive bladder cancer (MIBC), allowing many patients to potentially avoid cystectomy, according to the results of a...
Amivantamab in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer
In a phase Ib/II study (OrigAMI-1) reported in the Journal of Clinical Oncology, Oberstein et al found that the EGFR-MET bispecific antibody amivantamab-vmjw showed activity when used as monotherapy in patients with chemorefractory RAS/BRAF wild-type metastatic colorectal cancer. Study Details In...
RAS Inhibitor Daraxonrasib in Metastatic Pancreatic Cancer
The treatment landscape for advanced pancreatic cancer is shifting. The common RAS mutation is now targetable and the race for the most effective inhibitor is heating up. In mid-April, Revolution Medicines announced positive results from its phase III RASolute 302 clinical trial of daraxonrasib, an ...
Novel Therapies Improve Outcomes Across Hematologic Malignancies
In an effort to help clinicians stay current with rapidly evolving hematology-oncology literature, we are providing these concise, clinically focused summaries of important peer-reviewed studies. These summaries are intended to highlight key findings, study design, and outcomes that may inform...
Abiraterone Plus Olaparib Shows ‘Remarkable’ Survival in BRCA/ATM-Mutated Metastatic Castration-Resistant Prostate Cancer
Updated results from the phase II BRCAAway trial showed that first-line treatment with abiraterone and prednisone plus olaparib resulted in a median overall survival of more than 5 years in patients with metastatic castration-resistant prostate cancer harboring BRCA1/2 and/or ATM alterations.1...
What Is the Optimal Setting for T-DXd in Early Breast Cancer? Experts Debate
Trastuzumab deruxtecan (T-DXd) has claimed a large share of the HER2-positive breast cancer landscape, even finding room among tumors previously thought to be HER2-negative. The DESTINY series of trials are international studies investigating T-DXd as a potential treatment option for eligible...
